Erratum: Epidermal Growth Factor Receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer (Clinical Cancer Research(2004)10(8594–602)Doi:10.1158/1078-0432.CCR-04-0690);Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer

Clinical Cancer Research

Volumn 10, Issue 24, 2004, Pages 8594-8602

  Schiff, Bradley A ^a   McMurphy, Andrea B ^a   Jasser, Samar A ^a   Younes, Maher N ^a   Doan, Dao ^a   Yigitbasi, Orhan G ^a   Kim, Seungwon ^a   Zhou, Ge ^a   Mandal, Mahitosh ^a   Bekele, Benjamin N ^b   Holsinger, F Christopher ^a   Sherman, Steven I ^b   Yeung, Sai Ching ^b   El Naggar, Adel K ^a,b   Myers, Jeffrey N ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PACLITAXEL;

ANAPLASTIC CARCINOMA; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TARGETING; GROWTH INHIBITION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; NUDE MOUSE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; THYROID CANCER;

EID: 19944426526     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-19-2052     Document Type: Erratum

References (31)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer 1997;79:564-73.
3. McIver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 2001;130:1028-34.
4. Ullrich A, Coussens L, Hayflick JS, et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984;309:418-25.
5. Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem 1990;265:7709-12.
6. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990;61:203-12.
7. Aaronson SA. Growth factors and cancer. Science 1991;254:1146-53.
8. Marti U, Ruchti C, Kampf J, et al. Nuclear localization of epidermal growth factor and epidermal growth factor receptors in human thyroid tissues. Thyroid 2001;11:137-45.
9. van der Laan BF, Freeman JL, Asa SL. Expression of growth factors and growth factor receptors in normal and tumorous human thyroid tissues. Thyroid 1995;5:67-73.
10. Hoelting T, Siperstein AE, Clark OH, Duh QY. Epidermal growth factor enhances proliferation, migration, and invasion of follicular and papillary thyroid cancer in vitro and in vivo. J Clin Endocrinol Metab 1994;79:401-8.
11. Bechtner G, Schopohl D, Rafferzeder M, Gartner R, Welsch U. Stimulation of thyroid cell proliferation by epidermal growth factor is different from cell growth induced by thyrotropin or insulin-like growth factor I. Eur J Endocrinol 1996;134:639-48.
12. Lemoine NR, Hughes CM, Gullick WJ, Brown CL, Wynford-Thomas D. Abnormalities of the EGF receptor system in human thyroid neoplasia. Int J Cancer 1991;49:558-61.
13. Westermark K, Lundqvist M, Wallin G, et al. EGF-receptors in human normal and pathological thyroid tissue. Histopathology 1996;28:221-7.
14. Duh QY, Gum ET, Gerend PL, Raper SE, Clark OH. Epidermal growth factor receptors in normal and neoplastic thyroid tissue. Surgery 1985;98:1000-7.
15. Duh QY, Siperstein AE, Miller RA, Sancho JJ, Demeure MJ, Clark OH. Epidermal growth factor receptors and adenylate cyclase activity in human thyroid tissues. World J Surg 1990;4:410-8.
16. Mizukami Y, Nonomura A, Hashimoto T, et al. Immunohistochemical demonstration of epidermal growth factor and c-myc oncogene product in normal, benign and malignant thyroid tissues. Histopathology 1991;18:11-8.
17. Aasland R, Akslen LA, Varhaug JE, Lillehaug JR. Co-expression of the genes encoding transforming growth factor-α and its receptor in papillary carcinomas of the thyroid. Int J Cancer 1990;46:382-7.
18. Bergström JD, Westermark B, Heldin N-E. Epidermal growth factor receptor signaling activates Met in human anaplastic thyroid carcinoma cells. Exp Cell Res 2000;259:293-9.
19. Nicholson S, Richard J, Sainsbury C, et al. Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br J Cancer 1991;63:146-50.
20. Lipponen P, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer 1994;69:1120-5.
21. Akslen LA, Myking AO, Salvesen H, Varhaug JE. Prognostic impact of EGF-receptor in papillary thyroid carcinoma. Br J Cancer 1993;68:808-12.
22. Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2202;62:5749-54.
23. Ciardiello F. EGFR-targeted agents potentiate the antitumour activity of chemotherapy and radiotherapy. Signal 2002;2:4-11.
24. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenographs is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000;6:4885-92.
25. Ranson M. ZD1839 (Iressa): for more than just non-small cell lung cancer. Oncologist 2002;7(Suppl 4): 16-24.
26. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
27. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
28. Herbst RS. ZD1839: targeting the epidermal growth factor receptor in cancer therapy. Expert Opin Investig Drugs 2002;11:837-49.
29. Haugen DR, Akslen LA, Varhaug JE, Lillehaug JR. Demonstration of a TGF-α-EGF-receptor autocrine loop and c-myc protein overexpression in papillary thyroid carcinomas. Int J Cancer 1993;55:37-43.
30. Aasland R, Akslen LA, Varhaug JE, Lillehaug JR. Co-expression of the genes encoding transforming growth factor-α and its receptor in papillary carcinomas of the thyroid. Int J Cancer 1990;46:382-7.
31. Gorgoulis V, Aninos D, Priftis C, et al. Expression of epidermal growth factor, transforming growth factor-α and epidermal growth factor receptor in thyroid tumors. In Vivo 1992;6:291-6.